Revvity Partners with Eli Lilly to Launch AI Drug Discovery Platform
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 09 2026
0mins
Should l Buy LLY?
Source: NASDAQ.COM
- Collaborative Innovation: Revvity's partnership with Eli Lilly integrates Lilly's AI-driven predictive modeling platform, Lilly TuneLab, into the Revvity Signals platform, aiming to expand access to advanced AI tools for drug discovery and enhance research efficiency.
- Data Security Assurance: The collaboration establishes a scalable federated framework that allows biotech companies to apply Lilly's predictive models to their research programs while keeping proprietary data private and secure, ensuring both data confidentiality and research flexibility.
- Funding Support Initiative: Revvity and Lilly will jointly fund access for selected participants, including the use of Signals One and Signals Xynthetica software along with modeling credits, aiming to lower barriers to AI adoption across the biotech sector and promote technology proliferation.
- Integration Advantage: Lilly TuneLab offers AI and machine learning models trained on decades of Lilly research data, enhanced through federated learning, while Revvity's Signals platform integrates these models into existing scientific workflows, significantly boosting overall drug discovery efficiency.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy LLY?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 903.020
Low
950.00
Averages
1192
High
1500
Current: 903.020
Low
950.00
Averages
1192
High
1500
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, and market products in a single business segment called human pharmaceutical products. The Company manufacture and distribute its products through facilities in the United States, including Puerto Rico, and in Europe and Asia. The Company’s products are sold in approximately 90 countries. Its Cardiometabolic Health products Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound, and others. Its oncology products include Cyramza, Erbitux, Tyvyt, Verzenio, Retevmo, Jaypirca, and others. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. Its LillyDirect, a direct-to-patient digital health care platform, provides delivery of select Lilly medicines dispensed by third-party pharmacies to patients.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ELI LILLY: DEAL ANTICIPATED TO FINALIZE IN LATE 2026
- Transaction Closure: A transaction is expected to close in the second half of 2026.
- Future Outlook: The timeline indicates a significant event or change anticipated in the near future.
See More
ELI LILLY TO ACQUIRE KELONIA; SHAREHOLDERS TO RECEIVE UP TO $7 BILLION IN CASH UNDER AGREEMENT TERMS
- Acquisition Announcement: Lilly will acquire Kelonia under the terms of an agreement.
- Financial Details: Kelonia shareholders are set to receive up to $7.00 billion in cash.
See More
LILLY SET TO PURCHASE KELONIA THERAPEUTICS TO FURTHER DEVELOP IN VIVO CAR-T CELL THERAPIES
Acquisition Announcement: LILLY has announced its acquisition of KELONIA, a company specializing in advanced therapeutic solutions.
Focus on In Vivo CAR-T Cell Therapies: The acquisition aims to enhance LILLY's capabilities in developing in vivo CAR-T cell therapies, which are innovative treatments for various diseases.
See More
Dexcom Positioned to Benefit from Weight-Loss Drug Market Growth
- Significant Market Potential: According to Dexcom, over nine million patients in the U.S. eligible for third-party coverage are not using CGM devices, indicating a substantial untapped market that could significantly boost the company's revenue in the future.
- Clear Technological Advantage: Dexcom's CGM devices offer real-time monitoring capabilities that improve health outcomes for diabetes patients, and as GLP-1 weight-loss drugs gain popularity, the demand for CGMs is expected to rise, enhancing Dexcom's market position.
- High Competitive Barriers: Dexcom has established a strong competitive advantage, with many third-party companies developing devices compatible with its technology, and as its installed base grows, it attracts more patients into its ecosystem, creating a favorable network effect that further solidifies its market leadership.
- Promising Future Growth: Dexcom has seen substantial financial improvement over the past decade, and with the increasing adoption of CGM technology and expansion into new markets, the company is well-positioned to deliver strong returns over the next decade, capitalizing on vast market opportunities.
See More
Dexcom Positioned to Benefit from Weight Loss Drug Market Growth
- Vast Market Potential: Dexcom's continuous glucose monitoring devices are poised to benefit from the rapid growth of the weight loss drug market, which is expected to attract more diabetes patients to its products, thereby expanding its addressable market and enhancing revenue potential.
- Strong Competitive Advantage: Dexcom has established a robust competitive moat in the medical device sector, with many third-party companies developing devices compatible with its technology, creating a network effect that further enhances its market appeal.
- User Growth Trend: Research indicates that CGM usage grows faster among GLP-1 drug users compared to non-therapy users, suggesting that the proliferation of weight loss drugs will drive demand for Dexcom's products, boosting company performance.
- Underpenetrated Market: In the U.S., over nine million patients eligible for third-party coverage are not using CGM devices, providing Dexcom with opportunities to further expand its market share by entering new territories and launching its over-the-counter product, Stelo.
See More
Three Healthcare Stocks with Durable Competitive Moats
- Eli Lilly's Market Edge: Eli Lilly (LLY) solidifies its market share with popular weight loss drugs like Mounjaro and Zepbound, while the recent approval of the oral weight loss drug Foundayo is expected to drive future earnings growth.
- Vertex Pharmaceuticals' Patent Protection: Vertex Pharmaceuticals (VRTX) leads globally in cystic fibrosis drugs, with patent protection extending into the late 2030s, and ongoing innovation positions it for strong profitability and potential new product launches.
- Intuitive Surgical's Robotic Surgery Dominance: Intuitive Surgical (ISRG) maintains a dominant position with its Da Vinci surgical robots, as hospitals investing in these high-cost devices are likely to continue using them, reinforcing its market position.
- Training Advantage in the Industry: Most surgeons are trained on the Da Vinci system, creating a familiarity that leads hospitals to prefer this platform, thereby strengthening Intuitive Surgical's competitive moat.
See More
ELI LILLY: DEAL ANTICIPATED TO FINALIZE IN LATE 2026
- Transaction Closure: A transaction is expected to close in the second half of 2026.
- Future Outlook: The timeline indicates a significant event or change anticipated in the near future.
See More
ELI LILLY TO ACQUIRE KELONIA; SHAREHOLDERS TO RECEIVE UP TO $7 BILLION IN CASH UNDER AGREEMENT TERMS
- Acquisition Announcement: Lilly will acquire Kelonia under the terms of an agreement.
- Financial Details: Kelonia shareholders are set to receive up to $7.00 billion in cash.
See More
LILLY SET TO PURCHASE KELONIA THERAPEUTICS TO FURTHER DEVELOP IN VIVO CAR-T CELL THERAPIES
Acquisition Announcement: LILLY has announced its acquisition of KELONIA, a company specializing in advanced therapeutic solutions.
Focus on In Vivo CAR-T Cell Therapies: The acquisition aims to enhance LILLY's capabilities in developing in vivo CAR-T cell therapies, which are innovative treatments for various diseases.
See More
Dexcom Positioned to Benefit from Weight-Loss Drug Market Growth
- Significant Market Potential: According to Dexcom, over nine million patients in the U.S. eligible for third-party coverage are not using CGM devices, indicating a substantial untapped market that could significantly boost the company's revenue in the future.
- Clear Technological Advantage: Dexcom's CGM devices offer real-time monitoring capabilities that improve health outcomes for diabetes patients, and as GLP-1 weight-loss drugs gain popularity, the demand for CGMs is expected to rise, enhancing Dexcom's market position.
- High Competitive Barriers: Dexcom has established a strong competitive advantage, with many third-party companies developing devices compatible with its technology, and as its installed base grows, it attracts more patients into its ecosystem, creating a favorable network effect that further solidifies its market leadership.
- Promising Future Growth: Dexcom has seen substantial financial improvement over the past decade, and with the increasing adoption of CGM technology and expansion into new markets, the company is well-positioned to deliver strong returns over the next decade, capitalizing on vast market opportunities.
See More
Dexcom Positioned to Benefit from Weight Loss Drug Market Growth
- Vast Market Potential: Dexcom's continuous glucose monitoring devices are poised to benefit from the rapid growth of the weight loss drug market, which is expected to attract more diabetes patients to its products, thereby expanding its addressable market and enhancing revenue potential.
- Strong Competitive Advantage: Dexcom has established a robust competitive moat in the medical device sector, with many third-party companies developing devices compatible with its technology, creating a network effect that further enhances its market appeal.
- User Growth Trend: Research indicates that CGM usage grows faster among GLP-1 drug users compared to non-therapy users, suggesting that the proliferation of weight loss drugs will drive demand for Dexcom's products, boosting company performance.
- Underpenetrated Market: In the U.S., over nine million patients eligible for third-party coverage are not using CGM devices, providing Dexcom with opportunities to further expand its market share by entering new territories and launching its over-the-counter product, Stelo.
See More
Three Healthcare Stocks with Durable Competitive Moats
- Eli Lilly's Market Edge: Eli Lilly (LLY) solidifies its market share with popular weight loss drugs like Mounjaro and Zepbound, while the recent approval of the oral weight loss drug Foundayo is expected to drive future earnings growth.
- Vertex Pharmaceuticals' Patent Protection: Vertex Pharmaceuticals (VRTX) leads globally in cystic fibrosis drugs, with patent protection extending into the late 2030s, and ongoing innovation positions it for strong profitability and potential new product launches.
- Intuitive Surgical's Robotic Surgery Dominance: Intuitive Surgical (ISRG) maintains a dominant position with its Da Vinci surgical robots, as hospitals investing in these high-cost devices are likely to continue using them, reinforcing its market position.
- Training Advantage in the Industry: Most surgeons are trained on the Da Vinci system, creating a familiarity that leads hospitals to prefer this platform, thereby strengthening Intuitive Surgical's competitive moat.
See More
